Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAbcellera Biologics Inc

Abcellera Biologics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
12.12 USD -0.34 ( 2.73%)
Last update at 2026-11-11T20:52:00Z
VOLUME
2272477
Market Cap
3697.38M

Momentum Score

…

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.05
Low
12.95
High
52 Week Price Range
2.75
Low
12.58
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

AbCellera Biologics is a Canadian biotech that provides antibody discovery technology and partners with pharmaceutical companies to discover therapeutic antibodies using single-cell screening and AI-enabled high-throughput platforms. Long-term growth drivers include recurring collaboration and licensing revenue, expansion into more therapeutic areas, and potential royalties from successful partnered drugs.
Principal risks are revenue concentration and reliance on partners' clinical and regulatory outcomes, stiff competition from other discovery platforms and CROs, and variable earnings with possible continued losses.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.46
Dividend Yield
-
Revenue TTM
66.17M
Revenue Per Share
0.22
Gross Profit TTM
-131.60M
Debt / Equity
0.13
ROE
-17.30%
Net Debt
-11.79M
ROCE
-13.74%
Diluted EPS TTM
-0.55

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -177.59M -200.40M -174.03M 239.10M -2.21M
Net income -146.41M -162.86M -146.40M 158.52M -2.21M
Selling general administrative 83.23M 72.71M 61.00M 55.48M 2.75M
Selling and marketing expenses - 12.78M 14.18M 11.27M 1.26M
Gross profit 75.13M 28.83M 38.02M 418.99M 11.61M
Reconciled depreciation 28.82M 97.00M 30.89M 33.10M 17.25M
Ebit -177.59M -301.15M -223.05M 216.51M -2.00M
Ebitda -155.42M -204.15M -192.16M 276.25M -0.15M
Depreciation and amortization 22.17M 97.00M 30.89M 59.73M 1.85M
Non operating income net other - - - 22.59M 14.74M
Operating income -217.10M -314.77M -237.21M 216.51M -4.12M
Other operating expenses 292.23M 343.60M 275.23M 258.36M 13.95M
Interest expense - - - 4.04M 0.21M
Tax provision -31.18M -37.54M -27.63M 80.58M 65.69M
Interest income 28.33M 38.47M 42.25M 16.08M 3.33M
Net interest income 28.33M 38.47M 42.25M 12.03M -1.90M
Non recurring - - - 66.44M 45.52M
Income tax expense -31.18M -37.54M -27.63M 80.58M 65.69M
Total revenue 75.13M 28.83M 38.02M 485.42M 11.61M
Total operating expenses 292.23M 343.60M 275.23M 191.92M 13.95M
Cost of revenue - 97.00M 30.89M 66.44M 45.52M
Total other income expense net 39.51M 114.37M 63.18M 22.59M 1.91M
Net income from continuing ops -146.41M -162.86M -146.40M 158.52M 153.46M
Net income applicable to common shares - - - 158.52M 153.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1356.95M 1360.55M 1488.09M 1540.91M 1318.57M
Intangible assets 38.38M 42.11M 120.42M 131.50M 148.39M
Other current assets 8.17M 33.63M 20.91M 75.41M 21.25M
Total liab 215.59M 304.47M 335.78M 307.63M 292.84M
Total stockholder equity 1141.36M 1056.08M 1152.32M 1233.28M 1025.73M
Deferred long term liab - - - 33.18M 37.37M
Other current liab 19.74M 16.46M 61.28M 57.98M 77.47M
Common stock 802.34M 777.17M 753.20M 734.37M 722.43M
Capital stock 802.34M 777.17M 753.20M 734.37M 722.43M
Retained earnings -29.48M 116.93M 279.79M 426.19M 267.67M
Other liab - - - 112.64M 134.01M
Good will 47.81M 47.81M 47.81M 47.81M 47.81M
Other assets - - - 84.43M 30.64M
Cash 155.01M 156.32M 133.32M 386.54M 476.14M
Total current liabilities 64.31M 76.61M 119.01M 118.32M 120.68M
Current deferred revenue 13.53M 21.18M 26.07M 21.61M 7.54M
Net debt -11.79M -90.96M -55.94M -304.28M -439.73M
Short term debt 5.82M 4.62M 6.16M 5.58M 3.65M
Short long term debt total 143.22M 65.36M 77.38M 82.26M 36.41M
Other stockholder equity 372.73M 166.36M 121.05M 74.12M 35.36M
Property plant equipment - - - 217.25M 111.62M
Total current assets 728.23M 751.37M 871.99M 1025.49M 929.80M
Long term investments 62.58M 82.30M 65.94M 72.52M 50.31M
Net tangible assets - - - 1053.97M 829.53M
Short term investments 405.31M 469.29M 627.26M 499.95M 246.84M
Net receivables 153.40M 92.13M 64.38M 38.59M 160.58M
Inventory 6.34M 0.00M 1.11M 1.53M 1.67M
Accounts payable 25.23M 34.35M 25.51M 33.15M 32.02M
Accumulated other comprehensive income -4.23M -4.38M -1.72M -1.39M 0.28M
Common stock total equity - - - 734.37M 722.43M
Retained earnings total equity - - - 426.19M 267.67M
Non currrent assets other 51.95M 96.54M 94.24M 46.33M 23.23M
Non current assets total 628.72M 609.18M 616.11M 515.42M 388.77M
Capital lease obligations 143.22M 65.36M 77.38M 82.26M 36.41M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 52.94M 121.41M -213.85M -352.62M -277.43M
Change to liabilities - - - -76.32M 21.18M
Total cashflows from investing activities 87.75M 121.41M -221.11M -352.62M -332.25M
Net borrowings - - 11.59M -0.32M -0.95M
Total cash from financing activities 14.08M 12.77M 10.36M -1.63M -3.89M
Change to operating activities - - - -4.54M -8.02M
Net income -146.41M -162.86M -146.40M 158.52M 153.46M
Change in cash -28.37M 23.00M -254.04M -86.49M -92.97M
Begin period cash flow 183.62M 160.61M 414.65M 501.14M 594.12M
End period cash flow 155.25M 183.62M 160.61M 414.65M 501.14M
Total cash from operating activities -131.29M -108.56M -43.88M 277.36M 244.58M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 22.17M 97.00M 30.89M 33.10M 17.25M
Other cashflows from investing activities 566.57M 35.71M 25.31M -2.94M 3.63M
Change to inventory - - 18.25M - 40.92M
Change to account receivables -55.62M -75.12M -45.93M -22.71M -37.39M
Sale purchase of stock - - - - -0.01M
Other cashflows from financing activities 14.08M -0.73M -1.23M -1.30M -2.06M
Change to netincome - - - 55.91M 32.20M
Capital expenditures 42.77M 78.40M 77.51M 72.66M 58.45M
Change receivables - - - -22.71M -37.39M
Cash flows other operating - - - 153.01M 60.67M
Cash and cash equivalents changes - - - -76.89M -91.55M
Change in working capital -70.69M -25.84M 13.22M 29.82M 41.67M
Stock based compensation 55.79M 67.58M 64.18M 49.48M 30.65M
Other non cash items 7.85M -84.44M -7.74M 8.55M 3.57M
Free cash flow -174.07M -186.95M -121.38M 204.70M 186.13M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ABCL
Abcellera Biologics Inc		 -0.34
2.73%		 12.12 - 27.55 55.88 4.04 48.59 5.30
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Abcellera Biologics Inc

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6

604 559 9005

https://www.abcellera.com

562

Name Title Year Born
Dr. Carl L.G. Hansen Ph.D. CEO, Pres & Chairperson 1975
Mr. Andrew Booth M.B.A. Chief Financial Officer 1974
Dr. Veronique Lecault Ph.D. COO & Director 1985
Mr. Tryn T. Stimart Esq., J.D. Chief Legal Officer, Chief Compliance Officer & Corp. Sec. 1970
Dr. Ester Falconer Ph.D. Chief Technology Officer 1975
Mr. Bo Barnhart Ph.D. Scientific Director NA
Ms. Tiffany Chiu B.Sc., Ph.D. VP of Communications NA
Mr. Murray McCutcheon Ph.D. VP of Corp. Devel. NA
Alexandra Weirich M.Sc. Mang. of Marketing & Communications NA
Caitlin Webster CIPD, M.Sc. Sr. Mang. of People & Culture NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…